Cigna: Partnership with 1.1M physicians curbed patients’ opioid use by 25%

Cigna cut members’ opioid use by 25 percent through a collaboration with 1.1 million-plus physicians.

Advertisement

The reduction is a goal Cigna set out to achieve in May 2016. The insurer wanted to curb its members’ opioid use back to pre-epidemic levels by 2019, but attained that goal a year early.

Cigna launched several initiatives to realize its goal. Some of those actions included notifying physicians about opioid misuse or overuse based on prescriptions and benefit use, and working with 85,000-plus prescribers who treat patients with a pattern of high opioid prescriptions.

“We collaborated with Cigna very early on, looking at the opioid prescription habits of our physicians and trying to get our practice more commensurate with national guidelines,” said John Bertini, MD, of Renaissance Physicians in Houston. “Clearly the inappropriate use of opioids is detrimental to the health of the patient, their family and the community on many levels. As we work together to address this problem, we are enhancing the health of the populations of patients that we collectively serve.”

More articles on opioids:
65% of ED physicians prescribe more opioids than they think they do
American Dental Association backs 7-day opioid prescription limits: 4 things to know
White House favors single drug for opioid addiction treatment among prisoners: 5 things to know

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in GLP-1s

Advertisement

Comments are closed.